Global Longlife Hospital and Research Ltd
- Market cap
- ₹ 13 Cr.
- P/E
- 125.3x
- P/B
- 0.56x
- 52-week range
- 9 – 25.8
- ROE
- −7%
- ROCE
- −3.9%
- Dividend yield
- 0%
- Debt / equity
- 0
- Sector
- Healthcare Services
- Industry
- Hospital
- Listed on
- BSE SME
About
Global Longlife Hospital and Research Limited is an India-based company, which is a multi-specialty tertiary care hospital. The Company offers medical services across oncology, ophthalmology, allergy and immunology, pain management, pulmonology, anesthesiology, cardiology, dermatology, critical care, diabetes and endocrinology, gastrointestinal (GI) medicine, gynecology, infectious disease, nephrology and neurology. Its surgical services include cardiovascular thoracic surgery (CVTS), joint replacement & ortho, general surgery, onco surgery, GI surgery, neurosurgery, ear, nose, and throat (ENT), plastic surgery, trauma center, urology, laparoscopic surgery, gynecology, and more. Its radiology services include mammography, CT scan, ultrasound, endoscopy, and sonography. Its pathology services include microbiology, biochemistry, clinical pathology, cyto pathology, hematology, serology, and others. Its other services include dialysis, pharmacy, ambulance, dietary and physiotherapy.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Hospital: 41 companies →Global Longlife Hospital and Research Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)125.3 against a typical 48.9: pricier than most peers (1st = cheapest).36th of 40
- Sales growth−100% against a typical +21.1% from a year earlier.33rd of 34
- Share price, 3 months+2.2% against a typical −10.9%.9th of 34
- Size₹ 13.3 Cr. market value against a typical ₹ 1,306.7 Cr. (1st = largest).35th of 36
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 20 | 13 | 12 | 12 | 12 | 1 | 1 | 0 | 0 | 0 |
| Expenses | 13 | 12 | 10 | 9 | 10 | 4 | 4 | 0 | 1 | 0 |
| Operating Profit | 7 | 1 | 2 | 2 | 3 | −3 | −4 | −0 | −1 | −0 |
| OPM % | 33.9% | 9.8% | 15% | 19.3% | 22% | −255.9% | −656.9% | — | — | — |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 6 | −1 | 0 | 0 |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Profit before tax | 6 | −0 | 1 | 2 | 2 | −4 | 1 | −1 | −1 | −0 |
| Tax % | 0% | −78.3% | 29.3% | 35.4% | 39.8% | −19.1% | −11.6% | 2.9% | 123.7% | 0% |
| Net Profit | 6 | −0 | 1 | 1 | 1 | −3 | 1 | −1 | −1 | −0 |
| EPS in Rs | 8.81 | −0.14 | 0.72 | 1.02 | 0.98 | −3.07 | 1.18 | −0.99 | −1.26 | −0.38 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- −100%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 63%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- −32%
- TTM
- —
- 10 Years
- —
- 5 Years
- −2%
- 3 Years
- −9%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Global Longlife Hospital and Research Ltd | ₹ 12.34 | ₹ 13 Cr. | 125.3x | 0.6x | −7% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 64.9x | 13.4x | 22% | 7.8% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 71.5x | 9.9x | 14.3% | 17.2% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 67.9x | 7.3x | 11.1% | 11.7% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 102.6x | 9.3x | 9.7% | 9.2% |
| Narayana Hrudayalaya | ₹ 1,667.25 | ₹ 33,862 Cr. | 48.1x | 9.1x | 19.9% | 10.3% |
Management
- Hetal Ramniklal Thakkar
- Chief Financial Officer, Executive Director
- Tanvi Solanki
- Compliance Officer, Company Secretary
- Dhruv Sureshkumar Jani
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.